1
|
Efremova A, Kashirskaya N, Krasovskiy S, Melyanovskaya Y, Krasnova M, Mokrousova D, Bulatenko N, Kondratyeva E, Makhnach O, Bukharova T, Zinchenko R, Kutsev S, Goldshtein D. Comprehensive Assessment of CFTR Modulators' Therapeutic Efficiency for N1303K Variant. Int J Mol Sci 2024; 25:2770. [PMID: 38474016 DOI: 10.3390/ijms25052770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2023] [Revised: 02/05/2024] [Accepted: 02/12/2024] [Indexed: 03/14/2024] Open
Abstract
p.Asn1303Lys (N1303K) is a common missense variant of the CFTR gene, causing cystic fibrosis (CF). In this study, we initially evaluated the influence of CFTR modulators on the restoration of N1303K-CFTR function using intestinal organoids derived from four CF patients expressing the N1303K variant. The forskolin-induced swelling assay in organoids offered valuable insights about the beneficial effects of VX-770 + VX-661 + VX-445 (Elexacaftor + Tezacaftor + Ivacaftor, ETI) on N1303K-CFTR function restoration and about discouraging the prescription of VX-770 + VX-809 (Ivacaftor + Lumacaftor) or VX-770 + VX-661 (Ivacaftor + Tezacaftor) therapy for N1303K/class I patients. Then, a comprehensive assessment was conducted on an example of one patient with the N1303K/class I genotype to examine the ETI effect on the restoration of N1303K-CFTR function using in vitro the patient's intestinal organoids, ex vivo the intestinal current measurements (ICM) method and assessment of the clinical status before and after targeted therapy. All obtained results are consistent with each other and have proven the effectiveness of ETI for the N1303K variant. ETI produced a significant positive effect on forskolin-induced swelling in N1303K/class I organoids indicating functional improvement of the CFTR protein; ICM demonstrated that ETI therapy restored CFTR function in the intestinal epithelium after three months of treatment, and the patient improved his clinical status and lung function, increased his body mass index (BMI) and reduced the lung pathogenic flora diversity, surprisingly without improving the sweat test results.
Collapse
Affiliation(s)
- Anna Efremova
- Research Centre for Medical Genetics, Moscow 115522, Russia
| | - Nataliya Kashirskaya
- Research Centre for Medical Genetics, Moscow 115522, Russia
- Moscow Regional Research and Clinical Institute ("MONIKI"), Moscow 129110, Russia
| | - Stanislav Krasovskiy
- Research Centre for Medical Genetics, Moscow 115522, Russia
- Pulmonology Scientific Research Institute under Federal Medical and Biological Agency of Russian Federation, Moscow 115682, Russia
| | | | - Maria Krasnova
- Research Centre for Medical Genetics, Moscow 115522, Russia
| | | | | | | | - Oleg Makhnach
- Research Centre for Medical Genetics, Moscow 115522, Russia
| | | | - Rena Zinchenko
- Research Centre for Medical Genetics, Moscow 115522, Russia
| | - Sergey Kutsev
- Research Centre for Medical Genetics, Moscow 115522, Russia
| | | |
Collapse
|
2
|
Krasnova M, Efremova A, Mokrousova D, Bukharova T, Kashirskaya N, Kutsev S, Kondratyeva E, Goldshtein D. Advances in the Study of Common and Rare CFTR Complex Alleles Using Intestinal Organoids. J Pers Med 2024; 14:129. [PMID: 38392563 PMCID: PMC10890655 DOI: 10.3390/jpm14020129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Revised: 01/15/2024] [Accepted: 01/19/2024] [Indexed: 02/24/2024] Open
Abstract
Complex alleles (CAs) arise when two or more nucleotide variants are present on a single allele. CAs of the CFTR gene complicate the cystic fibrosis diagnosis process, classification of pathogenic variants, and determination of the clinical picture of the disease and increase the need for additional studies to determine their pathogenicity and modulatory effect in response to targeted therapy. For several different populations around the world, characteristic CAs of the CFTR gene have been discovered, although in general the prevalence and pathogenicity of CAs have not been sufficiently studied. This review presents examples of using intestinal organoid models for assessments of the two most common and two rare CFTR CAs in individuals with cystic fibrosis in Russia.
Collapse
Affiliation(s)
- Maria Krasnova
- Research Centre for Medical Genetics, Moscow 115522, Russia
| | - Anna Efremova
- Research Centre for Medical Genetics, Moscow 115522, Russia
| | | | | | - Nataliya Kashirskaya
- Research Centre for Medical Genetics, Moscow 115522, Russia
- Moscow Regional Research and Clinical Institute ("MONIKI"), Schepkina Street, 61/2, 1, Moscow 129110, Russia
| | - Sergey Kutsev
- Research Centre for Medical Genetics, Moscow 115522, Russia
| | | | | |
Collapse
|
3
|
Munck A, Southern KW, Murphy J, de Winter-de Groot KM, Gartner S, Karadag B, Kashirskaya N, Linnane B, Proesmans M, Sands D, Sommerburg O, Castellani C, Barben J. Cystic Fibrosis Cases Missed by Newborn Bloodspot Screening-Towards a Consistent Definition and Data Acquisition. Int J Neonatal Screen 2023; 9:65. [PMID: 38132824 PMCID: PMC10743499 DOI: 10.3390/ijns9040065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Revised: 11/13/2023] [Accepted: 11/14/2023] [Indexed: 12/23/2023] Open
Abstract
Repeated European surveys of newborn bloodspot screening (NBS) have shown varied strategies for collecting missed cases, and information on data collection differs among countries/regions, hampering data comparison. The ECFS Neonatal Screening Working Group defined missed cases by NBS as either false negatives, protocol-related, concerning analytical issues, or non-protocol-related, concerning pre- and post-analytical issues. A questionnaire has been designed and sent to all key workers identified in each NBS programme to assess the feasibility of collecting data on missed cases, the stage of the NBS programme when the system failed, and individual patient data on each missed case.
Collapse
Affiliation(s)
- Anne Munck
- Hospital Necker Enfants-Malades, AP-HP, CF Centre, University Paris Descartes, 75015 Paris, France;
| | - Kevin W. Southern
- Department of Women’s and Children’s Health, University of Liverpool, Liverpool L69 3BX, UK; (K.W.S.)
| | - Jared Murphy
- Department of Women’s and Children’s Health, University of Liverpool, Liverpool L69 3BX, UK; (K.W.S.)
| | - Karin M. de Winter-de Groot
- Department of Paediatric Pulmonology & Allergology, Wilhelmina Children’s Hospital, University Medical Centre Utrecht, Utrecht University, 3508 AB Utrecht, The Netherlands;
| | - Silvia Gartner
- Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain;
| | - Bülent Karadag
- Department of Pediatric Pulmonology, Marmara University, 34890 Istanbul, Turkey;
| | - Nataliya Kashirskaya
- Laboratory of Genetic Epidemiology, Research Centre for Medical Genetics, Moscow Regional Research and Clinical Institute, Moscow 115522, Russia;
| | - Barry Linnane
- School of Medicine and Centre for Interventions in Infection, Inflammation & Immunity (4i), University of Limerick, V94 T9PX Limerick, Ireland;
| | - Marijke Proesmans
- Division of Woman and Child, Department of Pediatrics, University Hospitals Leuven, 3000 Leuven, Belgium;
| | - Dorota Sands
- Cystic Fibrosis Department, Institute of Mother and Child, 01-211 Warsaw, Poland;
| | - Olaf Sommerburg
- Paediatric Pulmonology, Allergology & CF Centre, Department of Paediatrics III, University Hospital Heidelberg, 69120 Heidelberg, Germany;
- Translational Lung Research Center, German Lung Research Center, University Hospital Heidelberg, 69120 Heidelberg, Germany
| | - Carlo Castellani
- Cystic Fibrosis Center, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy;
| | - Jürg Barben
- Paediatric Pulmonology & CF Centre, Children’s Hospital of Eastern Switzerland, 9000 St. Gallen, Switzerland
| |
Collapse
|
4
|
Castellani C, Simmonds NJ, Barben J, Addy C, Bevan A, Burgel PR, Drevinek P, Gartner S, Gramegna A, Lammertyn E, Landau EEC, Middleton PG, Plant BJ, Smyth AR, van Koningsbruggen-Rietschel S, Girodon E, Kashirskaya N, Munck A, Nährlich L, Raraigh K, Sermet-Gaudelus I, Sommerburg O, Southern KW. Standards for the care of people with cystic fibrosis (CF): A timely and accurate diagnosis. J Cyst Fibros 2023; 22:963-968. [PMID: 37775442 DOI: 10.1016/j.jcf.2023.09.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2023] [Revised: 09/18/2023] [Accepted: 09/18/2023] [Indexed: 10/01/2023]
Abstract
There is considerable activity with respect to diagnosis in the field of cystic fibrosis (CF). This relates primarily to developments in newborn bloodspot screening (NBS), more extensive gene analysis and improved characterisation of CFTR-related disorder (CFTR-RD). This is particularly pertinent with respect to accessibility to variant-specific therapy (VST), a transformational intervention for people with CF with eligible CFTR gene variants. This advance reinforces the need for a timely and accurate diagnosis. In the future, there is potential for trials to assess effectiveness of variant-specific therapy for CFTR-RD. The guidance in this paper reaffirms previous standards, clarifies a number of issues, and integrates emerging evidence. Timely and accurate diagnosis has never been more important for people with CF.
Collapse
Affiliation(s)
- Carlo Castellani
- Cystic Fibrosis Center, IRCCS Istituto Giannina Gaslini, Genoa, Italy
| | - Nicholas J Simmonds
- Adult Cystic Fibrosis Centre, Royal Brompton Hospital and Imperial College, London, United Kingdom
| | - Jürg Barben
- Division of Paediatric Pulmonology & CF Centre, Children's Hospital of Eastern Switzerland, Claudiusstr. 6, St. Gallen 9006, Switzerland
| | - Charlotte Addy
- All Wales Adult Cystic Fibrosis Centre, University Hospital Llandough, Cardiff and Vale University Health Board, Cardiff, UK
| | - Amanda Bevan
- University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
| | - Pierre-Régis Burgel
- Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, Assistance Publique Hôpitaux de Paris (AP-HP) and Université Paris-Cité, Institut Cochin, Inserm U1016, Paris, France
| | - Pavel Drevinek
- Department of Medical Microbiology, Second Faculty of Medicine, Motol University Hospital, Charles University, Prague, Czech Republic
| | | | - Andrea Gramegna
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - Elise Lammertyn
- Cystic Fibrosis Europe, Brussels, Belgium and the Belgian CF Association, Brussels, Belgium
| | - Eddie Edwina C Landau
- The Graub CF Center, Pulmonary Institute, Schneider Children's Medical Center, Petah Tikva, Israel
| | - Peter G Middleton
- Westmead Clinical School, University of Sydney and CITRICA, Dept Respiratory & Sleep Medicine, Westmead Hospital, Westmead, Australia
| | - Barry J Plant
- Cork Centre for Cystic Fibrosis (3CF), Cork University Hospital, Cork, Ireland
| | - Alan R Smyth
- School of Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Belfast and NIHR Nottingham Biomedical Research Centre, Nottingham, UK
| | | | - Emmanuelle Girodon
- Molecular Genetics Laboratory, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France
| | - Nataliya Kashirskaya
- Laboratory of genetic epidemiology, Research Centre for Medical Genetics/Moscow Regional Research and Clinical Institute, Moscow, Russian Federation
| | - Anne Munck
- Hospital Necker Enfants-Malades, AP-HP, CF centre, Université Paris Descartes, Paris, France
| | - Lutz Nährlich
- Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany
| | - Karen Raraigh
- McKusick-Nathans Department of Genetic Medicine, Johns Hopkins University, Baltimore, United States
| | - Isabelle Sermet-Gaudelus
- 1 INSERM U1151, Institut Necker Enfants Malades, and Centre de Références Maladies Rares, Mucoviscidose et Maladies apparentées, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP)-Centre, and AP-HP, Hôpital Universitaire Necker-Enfants Malades, Service de Pneumologie Pédiatrique, Centre de Référence pour les Maladies Respiratoires Rares de l'Enfant, Paris, France
| | - Olaf Sommerburg
- Paediatric Pulmonology, Allergology & CF Centre, Department of Paediatrics III, and Translational Lung Research Center, German Lung Research Center, University Hospital Heidelberg, Germany
| | - Kevin W Southern
- Department of Women's and Children's Health, University of Liverpool, Liverpool, UK.
| |
Collapse
|
5
|
Munck A, Berger DO, Southern KW, Carducci C, de Winter-de Groot KM, Gartner S, Kashirskaya N, Linnane B, Proesmans M, Sands D, Sommerburg O, Castellani C, Barben J. European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance. J Cyst Fibros 2022:S1569-1993(22)00689-0. [PMID: 36372700 DOI: 10.1016/j.jcf.2022.09.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Revised: 09/27/2022] [Accepted: 09/28/2022] [Indexed: 11/12/2022]
Abstract
BACKGROUND The aim of this study was to record the current status of newborn bloodspot screening (NBS) for CF across Europe and assess performance. METHODS Survey of representatives of NBS for CF programmes across Europe. Performance was assessed through a framework developed in a previous exercise. RESULTS In 2022, we identified 22 national and 34 regional programmes in Europe. Barriers to establishing NBS included cost and political inertia. Performance was assessed from 2019 data reported by 21 national and 21 regional programmes. All programmes employed different protocols, with IRT-DNA the most common strategy. Six national and 11 regional programmes did not use DNA analysis. CONCLUSIONS Integrating DNA analysis into the NBS protocol improves PPV, but at the expense of increased carrier and CFSPID recognition. Some programmes employ strategies to mitigate these outcomes. Programmes should constantly strive to improve performance but large datasets are needed to assess outcomes reliably.
Collapse
Affiliation(s)
- Anne Munck
- Hospital Necker Enfants-Malades, AP-HP, CF centre, Université Paris Descartes, France, and CF referent physician for the French Society of Newborn Screenings
| | - Daria O Berger
- ECFS NSWG Data Manager, Institute of Social and Preventive Medicine and Graduate School for Health Sciences, University of Bern, Switzerland
| | - Kevin W Southern
- Department of Women's and Children's Health, University of Liverpool, United Kingdom
| | - Carla Carducci
- Department of Experimental Medicine, Sapienza University, Rome Italy
| | - Karin M de Winter-de Groot
- Department of Paediatric Pulmonology & Allergology, Wilhelmina Children's Hospital/University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands
| | - Silvia Gartner
- Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Universitari Vall d´Hebron, Barcelona, Spain
| | - Nataliya Kashirskaya
- Laboratory of genetic epidemiology, Research Centre for Medical Genetics/Moscow Regional Research and Clinical Institute, Moscow, Russian Federation
| | - Barry Linnane
- Graduate Entry Medical School and Centre for Interventions in Infection, Inflammation & Immunity (4i), University of Limerick, Limerick, Ireland
| | - Marijke Proesmans
- Division of Woman and Child, Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium
| | - Dorota Sands
- Cystic Fibrosis Department, Institute of Mother and Child, Warsaw, Poland
| | - Olaf Sommerburg
- Paediatric Pulmonology, Allergology & CF Centre, Department of Paediatrics III, and Translational Lung Research Center, German Lung Research Center, University Hospital Heidelberg, Germany
| | - Carlo Castellani
- IRCCS Istituto Giannina Gaslini, Cystic Fibrosis Center, Genoa, Italy
| | - Jürg Barben
- Paediatric Pulmonology & CF Centre, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland.
| | | |
Collapse
|
6
|
Carr SB, McClenaghan E, Elbert A, Faro A, Cosgriff R, Abdrakhmanov O, Brownlee K, Burgel PR, Byrnes CA, Cheng SY, Colombo C, Corvol H, Daneau G, Goss CH, Gulmans V, Gutierrez H, Harutyunyan S, Helmick M, Jung A, Kashirskaya N, McKone E, Melo J, Middleton PG, Mondejar-Lopez P, de Monestrol I, Nährlich L, Padoan R, Parker M, Pastor-Vivero MD, Rizvi S, Ruseckaite R, Salvatore M, da Silva-Filho LVRF, Versmessen N, Zampoli M, Marshall BC, Stephenson AL. Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study. J Cyst Fibros 2022; 21:e221-e231. [PMID: 35753987 PMCID: PMC9189103 DOI: 10.1016/j.jcf.2022.06.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Revised: 05/19/2022] [Accepted: 06/11/2022] [Indexed: 01/02/2023]
Abstract
BACKGROUND This international study aimed to characterise the impact of acute SARS-CoV-2 infection in people with cystic fibrosis and investigate factors associated with severe outcomes. Methods Data from 22 countries prior to 13th December 2020 and the introduction of vaccines were included. It was de-identified and included patient demographics, clinical characteristics, treatments, outcomes and sequalae following SARS-CoV-2 infection. Multivariable logistic regression was used to investigate factors associated with clinical progression to severe COVID-19, using the primary outcome of hospitalisation with supplemental oxygen. RESULTS SARS-CoV-2 was reported in 1555 people with CF, 1452 were included in the analysis. One third were aged <18 years, and 9.4% were solid-organ transplant recipients. 74.5% were symptomatic and 22% were admitted to hospital. In the non-transplanted cohort, 39.5% of patients with ppFEV1<40% were hospitalised with oxygen verses 3.2% with ppFEV >70%: a 17-fold increase in odds. Worse outcomes were independently associated with older age, non-white race, underweight body mass index, and CF-related diabetes. Prescription of highly effective CFTR modulator therapies was associated with a significantly reduced odds of being hospitalised with oxygen (AOR 0.43 95%CI 0.31-0.60 p<0.001). Transplanted patients were hospitalised with supplemental oxygen therapy (21.9%) more often than non-transplanted (8.8%) and was independently associated with the primary outcome (Adjusted OR 2.45 95%CI 1.27-4.71 p=0.007). CONCLUSIONS This is the first study to show that there is a protective effect from the use of CFTR modulator therapy and that people with CF from an ethnic minority are at more risk of severe infection with SARS-CoV-2.
Collapse
Affiliation(s)
- Siobhán B Carr
- Royal Brompton Hospital, part of GSST NHS Foundation Trust, London, UK; NHLI, Imperial College, London, UK.
| | - Elliot McClenaghan
- Cystic Fibrosis Trust, London, UK; London School of Hygiene and Tropical Medicine, London, UK
| | | | | | | | | | | | - Pierre-Régis Burgel
- Université de Paris, Inserm U1016, Institut Cochin and Cochin Hospital, Assistance Publique Hôpitaux de Paris (APHP), France
| | - Catherine A Byrnes
- Starship Children's Hospital and University of Auckland, Auckland, New Zealand
| | | | - Carla Colombo
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Italy
| | - Harriet Corvol
- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Assistance Publique Hôpitaux de Paris (APHP), Hôpital Trousseau, Service de Pneumologie Pédiatrique, Paris, France
| | | | | | | | | | | | | | - Andreas Jung
- University Children's Hospital, Zurich, Switzerland
| | | | | | | | | | | | - Isabelle de Monestrol
- Department of Pediatrics, CLINTEC, Karolinska Institutet; Karolinska University Hospital Huddinge, Sweden
| | - Lutz Nährlich
- Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany
| | - Rita Padoan
- Cystic Fibrosis Support Center, Department of Paediatric, University of Brescia, Italy
| | | | | | | | | | - Marco Salvatore
- Istituto Superiore di Sanita, National Center Rare Diseases, Undiagnosed Rare Diseases Interdepartmental Unit, Rome, Italy
| | | | | | - Marco Zampoli
- University of Cape Town and Red Cross War Memorial Children's Hospital, South Africa
| | | | - Anne L Stephenson
- Cystic Fibrosis, Canada; Toronto Adult Cystic Fibrosis Centre, St. Michael's Hospital, Toronto, Canada
| |
Collapse
|
7
|
Voronkova A, Kondratieva E, Kutsev S, Kashirskaya N, Krasovsky S, Amelina E, Polyakov A, Zinchenko R, Petrova N, Adyan T, Melyanovskaya J, Asherova I, Arsen AB, Bulatovа I, Vasilieva T, Gembitskaya T, Gorinova J, Zhekaite E, Sherman V, Ilyenkova N, Kalinina Y, Karimova I, Kondakova Y, Kuzmicheva I, Ledneva V, Lyagusha D, Moskvina D, Nazarenko L, Novikova O, Pavlov P, Petrov V, Pinegina Y, Protasova T, Pyaterkina O, Rybalkina M, Safonova T, Sergienko D, Simanova T, Stepanenko T, Filimonova T, Shadrina V, Shulyak I, Goryainova A, Orlov A. P068 Characteristics of genetic variants of the CFTR gene in the Russian Federation according to the 2020 Registry. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00401-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
8
|
Enina E, Kondratyeva E, Zinchenko R, Starinova M, Vodovozova E, Ledeneva L, Kashirskaya N, Gorinova Y, Voronkova A, Krasovskyi S, Amelina E, Kirichenko N. P010 Genotype features in patients with cystic fibrosis in the North Caucasus Federal District of the Russian Federation. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00346-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
9
|
Kondratyeva E, Amelina E, Kutsev S, Tyumentseva E, Voronkova A, Krasovsky S, Polyakov A, Zhekaite E, Sherman V, Adyan T, Melyanovskaya Y, Kashirskaya N, Starinova M, Akeliev S, Ayupova G, Vasilieva E, Gaimolenko I, Golubtsova O, Goryainova A, Gubareva T, Dubova N, Diachkova A, Zakurnaeva E, Kozlova E, Lavrova A, Lakhova E, Mambetova A, Nedashkovskaya N, Ochirova N, Pashkevich A, Petrova A, Ponomareva N, Pushkareva D, Revel-Muroz N, Reutskaya E, Satsuk N, Smirnova T, Stashkevich T, Stezhkina E, Trishina S, Tutueva L, Shakhgireeva M, Yagubyants E, Simonova O, Semykin S, Gorinova J. P067 The main characteristics of cystic fibrosis patients: National Patient Registry of Russia (RCFPR) 2020. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00400-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Zampoli M, Kashirskaya N, Karadag B, Filho LVRFDS, Paul GR, Noke C. Global access to affordable CFTR modulator drugs: Time for action! J Cyst Fibros 2022; 21:e215-e216. [PMID: 35341695 DOI: 10.1016/j.jcf.2022.03.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Accepted: 03/14/2022] [Indexed: 11/26/2022]
Affiliation(s)
- Marco Zampoli
- Clinical Head: Cystic Fibrosis Clinic Red Cross War Memorial Children's Hospital, National Director South African CF Registry Steering Committee, Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
| | - Nataliya Kashirskaya
- Laboratory of Genetic Epidemiology Research Centre for Medical Genetics, Moscow Regional Research and Clinical Institute, President of All-Russian Association For Patients With Cystic Fibrosis, Moscow, Russian Federation
| | - Bulent Karadag
- Division of Pediatric Pulmonology, Marmara University, Istanbul, Turkey
| | | | - Grace R Paul
- Division of Pulmonary and Sleep Medicine, Nationwide Children's Hospital, The Ohio State University, Columbus, OH, United States of America
| | - Christine Noke
- Middle East Cystic Fibrosis Association CEO of (MECFA), United States of America
| |
Collapse
|
11
|
Drzymała-Czyż S, Dziedzic K, Szwengiel A, Krzyżanowska-Jankowska P, Nowak JK, Nowicka A, Aringazina R, Drzymała S, Kashirskaya N, Walkowiak J. Serum bile acids in cystic fibrosis patients - glycodeoxycholic acid as a potential marker of liver disease. Dig Liver Dis 2022; 54:111-117. [PMID: 34305015 DOI: 10.1016/j.dld.2021.06.034] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/10/2021] [Revised: 06/22/2021] [Accepted: 06/30/2021] [Indexed: 12/30/2022]
Abstract
BACKGROUND Cystic fibrosis (CF) and CF-related liver disease can lead to disturbances in bile acid metabolism. AIM This study determined serum bile acid concentrations in CF to define their usefulness in liver disease assessment. METHODS Primary, secondary and conjugated bile acid levels were measured in three CF groups (25 patients each) exhibiting: liver cirrhosis, other liver disease, no liver disease, and in 25 healthy subjects (HS). RESULTS Bile acid levels were higher in CF patients than in HS, except for glycodeoxycholic acid (GDCA). However, bile acid concentrations did not differ between patients with cirrhosis and other liver involvement. GDCA and deoxycholic acid (DCA) differentiated CF patients with non-cirrhotic liver disease from those without liver disease (GDCA-AUC: 0.924, 95%CI 0.822-1.000, p<0.001; DCA-AUC: 0.867, 95%CI: 0.731-1.000, p<0.001). Principal component analysis revealed that in CF liver disease was related to GDCA, GGTP activity, severe genotype and pancreatic insufficiency. CONCLUSIONS A CF-specific bile acid profile was defined and shown to relate to liver disease. GDCA differentiates patients with non-cirrhotic liver involvement from those with no detectable liver disease. Hence, GDCA is a candidate for validation as a biomarker of non-cirrhotic progression of liver disease in CF.
Collapse
Affiliation(s)
- Sławomira Drzymała-Czyż
- Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznań, Poland; Department of Bromatology, Poznan University of Medical Sciences, Poznań, Poland
| | - Krzysztof Dziedzic
- Department of Food Science and Nutrition, Institute of Food Technology of Plant Origin, Poznań University of Life Sciences, Poznań, Poland
| | - Artur Szwengiel
- Department of Food Science and Nutrition, Institute of Food Technology of Plant Origin, Poznań University of Life Sciences, Poznań, Poland
| | | | - Jan K Nowak
- Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznań, Poland
| | - Agata Nowicka
- Department of Pulmonology, Allergology and Respiratory Oncology, Poznan University of Medical Sciences, Poznań, Poland
| | - Raisa Aringazina
- Department of Internal Diseases No1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
| | - Sylwia Drzymała
- Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznań, Poland
| | - Nataliya Kashirskaya
- Department of Genetic Epidemiology (Cystic Fibrosis Group), Research Centre for Medical Genetics, Moscow, Russia
| | - Jarosław Walkowiak
- Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznań, Poland.
| |
Collapse
|
12
|
Kashirskaya N, Petrova N, Marakhonov A, Kutsev S, Zinchenko R. 646: Frequency of CFTR complex alleles associated with p.Phe508del in Russian cystic fibrosis patients. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)02069-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
13
|
Moskalets Y, Mileshina N, Barylyak V, Kashirskaya N, Walkowiak J. 93: Hearing impairment in children with cystic fibrosis. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01518-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
Munck A, Southern KW, Castellani C, de Winter-de Groot KM, Gartner S, Kashirskaya N, Linnane B, Mayell SJ, Proesmans M, Sands D, Sommerburg O, Barben J. Defining key outcomes to evaluate performance of newborn screening programmes for cystic fibrosis. J Cyst Fibros 2021; 20:820-823. [DOI: 10.1016/j.jcf.2021.02.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Revised: 02/05/2021] [Accepted: 02/06/2021] [Indexed: 10/22/2022]
|
15
|
Nowak JK, Wykrętowicz A, Mądry E, Krauze T, Drzymała-Czyż S, Krzyżanowska-Jankowska P, Sobkowiak P, Schneider A, Goździk-Spychalska J, Kurek S, Kononets V, Kashirskaya N, Lisowska A, Walkowiak J. Preclinical atherosclerosis in cystic fibrosis: Two distinct presentations are related to pancreatic status. J Cyst Fibros 2021; 21:26-33. [PMID: 34253491 DOI: 10.1016/j.jcf.2021.06.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 06/11/2021] [Accepted: 06/23/2021] [Indexed: 11/25/2022]
Abstract
BACKGROUND Patients with cystic fibrosis (CF) are exposed to overlapping cardiovascular risk factors. We hypothesized that CF is characterized by increased arterial stiffness and greater intima-media thickness (IMT). METHODS This cross-sectional study assessed the digital volume pulse arterial stiffness index (SIDVP) using photopletysmography, measured intima-media complex thickness (IMT) at the common carotid artery, and obtained an extended set of clinical and atherosclerosis-related laboratory parameters. RESULTS Fifty-five patients with moderate-to-severe CF (mean age 26.3±8.6 years, BMI 20.3±3.1 kg/m2, FEV1 62±26%) and 51 healthy controls (25.1±4.4 years, BMI 21.7±3.0 kg/m2) entered the study. SIDVP was greater in pancreatic insufficient (PI), but not pancreatic sufficient (PS) CF patients compared with control (7.3±1.8 m/s vs 6.0±1.2 m/s; p=7.1 × 10-5). IMT was increased in PS (but not PI) participants relative to control (552±69 µm vs 456±95 µm, p=0.0011). SIDVP was also greater in PI than in PS patients (7.3±1.8 m/s vs 6.3±1.7 m/s, p=0.0232) and IMT was higher in PS compared with PI (552±69 µm vs 453±82 µm, p=0.0002). SIDVP independently associated with age, PI, the lack of liver cirrhosis, and with Pseudomonas aeruginosa colonization. PS was the only independent correlate of IMT in CF. CONCLUSIONS PI patients are at risk of developing general arterial stiffness. PS may relate to carotid IMT thickening, which underscores the need for further study that could lead to reconsideration of dietary guidance in PS CF.
Collapse
Affiliation(s)
- Jan Krzysztof Nowak
- Poznan University of Medical Sciences, Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan, Poland
| | - Andrzej Wykrętowicz
- Poznan University of Medical Sciences, Department of Cardiology-Intensive Therapy, Poznan, Poland
| | - Edyta Mądry
- Poznan University of Medical Sciences, Department of Physiology, Poznan, Poland
| | - Tomasz Krauze
- Poznan University of Medical Sciences, Department of Cardiology-Intensive Therapy, Poznan, Poland
| | - Sławomira Drzymała-Czyż
- Poznan University of Medical Sciences, Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan, Poland; Poznan University of Medical Sciences, Department of Bromatology, Poznan, Poland
| | | | - Paulina Sobkowiak
- Poznan University of Medical Sciences, Department of Pediatric Pneumonology, Allergology and Clinical Immunology, Poznan, Poland
| | - Agata Schneider
- Poznan University of Medical Sciences, Department of Cardiology-Intensive Therapy, Poznan, Poland
| | - Joanna Goździk-Spychalska
- Poznan University of Medical Sciences, Department of Pulmonology, Allergology and Respiratory Oncology, Poznan, Poland
| | - Szymon Kurek
- Poznan University of Medical Sciences, Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan, Poland
| | - Victoria Kononets
- West Kazakhstan Marat Ospanov Medical University, Department of Natural Sciences Disciplines, Aktobe, Kazakhstan
| | - Nataliya Kashirskaya
- Research Centre for Medical Genetics, Department of Genetic Epidemiology, Cystic Fibrosis Group, Moscow, Russia
| | - Aleksandra Lisowska
- Poznan University of Medical Sciences, Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan, Poland
| | - Jarosław Walkowiak
- Poznan University of Medical Sciences, Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan, Poland.
| |
Collapse
|
16
|
Petrova N, Balinova N, Marakhonov A, Vasilyeva T, Kashirskaya N, Galkina V, Ginter E, Kutsev S, Zinchenko R. Ethnic Differences in the Frequency of CFTR Gene Mutations in Populations of the European and North Caucasian Part of the Russian Federation. Front Genet 2021; 12:678374. [PMID: 34220950 PMCID: PMC8242336 DOI: 10.3389/fgene.2021.678374] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Accepted: 05/12/2021] [Indexed: 11/13/2022] Open
Abstract
Cystic fibrosis (CF) is a common monogenic disease caused by pathogenic variants in the CFTR gene. The distribution and frequency of CFTR variants vary in different countries and ethnic groups. The spectrum of pathogenic variants of the CFTR gene was previously studied in more than 1,500 CF patients from different regions of the European and North Caucasian region of Russia and the spectrum of the most frequent pathogenic variants of the CFTR gene and ethnic features of their distribution were determined. To assess the population frequency of CFTR gene mutations some of the common variants were analyzed in the samples of healthy unrelated individuals from the populations of the European part of the Russian Federation: 1,324 Russians from four European regions (Pskov, Tver, Rostov, and Kirov regions), representatives of five indigenous ethnic groups of the Volga-Ural region [Mari (n = 505), Udmurts (n = 613), Chuvash (n = 780), Tatars (n = 704), Bashkirs (n = 517)], and six ethnic groups of the North Caucasus [Karachay (n = 324), Nogais (n = 118), Circassians (n = 102), Abazins (n = 128), Ossetians (n = 310), and Chechens (n = 100)]. The frequency of common CFTR mutations was established in studied ethnic groups. The frequency of F508del mutation in Russians was found to be 0.0056 on average, varying between four regions, from 0.0027 in the Pskov region to 0.0069 in the Rostov region. Three variants W1282X, 1677delTA, and F508del were identified in the samples from the North Caucasian populations: in Karachay, the frequency of W1282X mutation was 0.0092, 1677delTA mutation - 0.0032; W1282X mutation in the Nogais sample - 0.0127, the frequency of F508del mutations was 0.0098 and 1677delTA - 0.0098 in Circassians; in Abazins F508del (0.0039), W1282X (0.0039) and 1677delTA (0.0117) mutations were found. In the indigenous peoples of the Volga-Ural region, the maximum frequency of the F508del mutation was detected in the Tatar population (0.099), while this mutation was never detected in the Mari and Bashkir populations. The E92K variant was found in Chuvash and Tatar populations. Thus, interethnic differences in the spectra of CFTR gene variants were shown both in CF patients and in healthy population of the European and North Caucasian part of Russia.
Collapse
Affiliation(s)
- Nika Petrova
- Research Centre for Medical Genetics, Moscow, Russia
| | | | | | | | | | | | | | - Sergey Kutsev
- Research Centre for Medical Genetics, Moscow, Russia
| | - Rena Zinchenko
- Research Centre for Medical Genetics, Moscow, Russia
- N.A. Semashko National Research Institute of Public Health, Moscow, Russia
| |
Collapse
|
17
|
Colombo C, Alicandro G, Oliver M, Lewindon PJ, Ramm GA, Ooi CY, Alghisi F, Kashirskaya N, Kondratyeva E, Corti F, Padoan R, Asherova I, Evans H, de Monestrol I, Strandvik B, Lindblad A. Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study. J Cyst Fibros 2021; 21:220-226. [PMID: 33814323 DOI: 10.1016/j.jcf.2021.03.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 03/10/2021] [Accepted: 03/15/2021] [Indexed: 12/19/2022]
Abstract
BACKGROUND The efficacy and safety of ursodeoxycholic acid (UDCA) for the treatment of liver disease associated with cystic fibrosis (CF) are under discussion, and clinical practice varies among centers. The study aimed at evaluating if the incidence of severe liver disease differs between CF centers routinely prescribing or not prescribing UDCA. METHODS We carried out a retrospective multicenter cohort study including 1591 CF patients (1192 patients from UDCA-prescribing centers and 399 from non-prescribing centers) born between 1990 and 2007 and followed from birth up to 31 December 2016. We computed the crude cumulative incidence (CCI) of portal hypertension (PH) at the age of 20 years in the two groups and estimated the subdistribution hazard ratio (HR) through a Fine and Gray model. RESULTS Over the observation period, 114 patients developed PH: 90 (7.6%) patients followed-up in UDCA prescribing centers and 24 (6.0%) in non-prescribing centers. The CCI of PH at 20 years was 10.1% (95% CI: 7.9-12.3) in UDCA-prescribing and 7.7% (95% CI: 4.6-10.7) in non-prescribing centers. The HR among patients followed in prescribing centers indicated no significant difference in the rate of PH either in the unadjusted model (HR: 1.21, 95% CI: 0.69-2.11) or in the model adjusted for pancreatic insufficiency (HR: 1.28, 95% CI: 0.77-2.12). CONCLUSIONS CF patients followed-up in UDCA prescribing centers did not show a lower incidence of PH as compared to those followed in centers not prescribing UDCA. These results question the utility of UDCA in reducing the occurrence of severe liver disease in CF.
Collapse
Affiliation(s)
- Carla Colombo
- IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy.
| | - Gianfranco Alicandro
- Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy
| | - Mark Oliver
- Royal Children's Hospital, Melbourne, Australia
| | | | - Grant A Ramm
- QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Chee Y Ooi
- Sydney Children's Hospital & School of Women's and Children's Health, Medicine, University of New South Wales, Sydney, Australia
| | | | - Nataliya Kashirskaya
- Federal State Budgetary Scientific Institution «Research Centre for Medical Genetics», Moscow, Russia
| | - Elena Kondratyeva
- Federal State Budgetary Scientific Institution «Research Centre for Medical Genetics», Moscow, Russia
| | - Fabiola Corti
- IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | | | | | - Helen Evans
- Starship Children's Health, Auckland, New Zealand
| | | | - Birgitta Strandvik
- Department of Bioscience and Nutrition, Karolinska Institutet, Stockholm, Sweden
| | | | | |
Collapse
|
18
|
Avetisyan L, Chernukha M, Siyanova E, Medvedeva O, Burmistrov E, Rusakova E, Kondrateva E, Voronkova A, Krasovskiy S, Zhekayte E, Kashirskaya N, Ginzburg A. P143 Microevolution of Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01169-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
19
|
Marnat E, Sorokina T, Shtaut M, Sedova A, Adyan T, Stepanova A, Beskorovaynaya T, Polyakov A, Kurilo L, Kashirskaya N, Chernykh V. P004 CFTR genotype in Russian patients with CBAVD syndrome. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01031-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
20
|
Bain R, Cosgriff R, Zampoli M, Elbert A, Burgel PR, Carr SB, Castaños C, Colombo C, Corvol H, Faro A, Goss CH, Gutierrez H, Jung A, Kashirskaya N, Marshall BC, Melo J, Mondejar-Lopez P, de Monestrol I, Naehrlich L, Padoan R, Pastor-Vivero MD, Rizvi S, Salvatore M, Filho LVRFDS, Brownlee KG, Haq IJ, Brodlie M. Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study. J Cyst Fibros 2021; 20:25-30. [PMID: 33309057 PMCID: PMC7713571 DOI: 10.1016/j.jcf.2020.11.021] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Accepted: 11/29/2020] [Indexed: 12/26/2022]
Abstract
BACKGROUND The presence of co-morbidities, including underlying respiratory problems, has been identified as a risk factor for severe COVID-19 disease. Information on the clinical course of SARS-CoV-2 infection in children with cystic fibrosis (CF) is limited, yet vital to provide accurate advice for children with CF, their families, caregivers and clinical teams. METHODS Cases of SARS-CoV-2 infection in children with CF aged less than 18 years were collated by the CF Registry Global Harmonization Group across 13 countries between 1 February and 7 August 2020. RESULTS Data on 105 children were collated and analysed. Median age of cases was ten years (interquartile range 6-15), 54% were male and median percentage predicted forced expiratory volume in one second was 94% (interquartile range 79-104). The majority (71%) of children were managed in the community during their COVID-19 illness. Out of 24 children admitted to hospital, six required supplementary oxygen and two non-invasive ventilation. Around half were prescribed antibiotics, five children received antiviral treatments, four azithromycin and one additional corticosteroids. Children that were hospitalised had lower lung function and reduced body mass index Z-scores. One child died six weeks after testing positive for SARS-CoV-2 following a deterioration that was not attributed to COVID-19 disease. CONCLUSIONS SARS-CoV-2 infection in children with CF is usually associated with a mild illness in those who do not have pre-existing severe lung disease.
Collapse
Affiliation(s)
- Robert Bain
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
| | | | - Marco Zampoli
- Division of Paediatric Pulmonology, Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, University of Cape Town, South Africa
| | | | - Pierre-Régis Burgel
- Respiratory Medicine and National Reference CF Center, AP-HP Hôpital Cochin, Paris, France; Université de Paris, Institut Cochin, Inserm U-1016, Paris, France
| | - Siobhán B Carr
- Royal Brompton Hospital and Imperial College London, United Kingdom
| | - Claudio Castaños
- Department of Pulmonology, Hospital de Pediatria JP Garrahan, Buenos Aires, Argentina
| | - Carla Colombo
- CF Regional Reference Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Italy
| | - Harriet Corvol
- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Assistance Publique Hôpitaux de Paris (APHP), Hôpital Trousseau, Service de Pneumologie Pédiatrique, Paris, France
| | - Albert Faro
- Cystic Fibrosis Foundation, Bethesda, MD, United States
| | - Christopher H Goss
- Department of Medicine and Pediatrics, University of Washington, Seattle, WA, United States
| | - Hector Gutierrez
- Pediatric Pulmonary and Sleep Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States
| | - Andreas Jung
- Department of Pulmonology and Children's Research Centre, University Children's Hospital Zurich, Zurich, Switzerland
| | - Nataliya Kashirskaya
- Laboratory of Genetic Epidemiology, Research Centre for Medical Genetics, Moscow, Russian Federation
| | | | - Joel Melo
- Instituo Nacional del Tórax, Santiago, Chile
| | - Pedro Mondejar-Lopez
- Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain
| | - Isabelle de Monestrol
- Stockholm Cystic Fibrosis Centre Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
| | - Lutz Naehrlich
- Universities of Giessen and Marburg Lung Center, German Center of Lung Research, Justus-Liebig-University Giessen, Giessen, Germany
| | - Rita Padoan
- Cystic Fibrosis Support Center, Department of Paediatric, University of Brescia, Italy
| | - Maria Dolores Pastor-Vivero
- Pediatric Pulmonology and Cystic Fibrosis Unit, Osakidetza, Hospital Universitario Cruces, Barakado, Bizkaia, Spain
| | - Samar Rizvi
- Cystic Fibrosis Foundation, Bethesda, MD, United States
| | - Marco Salvatore
- National Center Rare Diseases, Undiagnosed Rare Diseases Interdepartmental Unit Istituto Superiore di Sanità, Rome, Italy
| | | | | | - Iram J Haq
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom; Paediatric Respiratory Medicine, Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
| | - Malcolm Brodlie
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom; Paediatric Respiratory Medicine, Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
| |
Collapse
|
21
|
Petrova N, Kashirskaya N, Kondratyeva E, Voronkova A, Vasilyeva T, Balinova N, Kutsev S, Zinchenko R. P006 The complex allele c.[1399C>T;1521_1523delCTT] (L467F;F508del) of the CFTR gene in Russian cystic fibrosis patients. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01033-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
22
|
Chernukha M, Avetisyan L, Siyanova E, Medvedeva O, Rusakova E, Kondrateva E, Voronkova A, Krasovskiy S, Sherman V, Kashirskaya N, Amelina E, Ginzburg A. P144 Mutations in chromosomal genes responsible for T3SS of Pseudomonas aeruginosa strains isolated from cystsic fibrosis patient lungs. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01170-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
McClenaghan E, Cosgriff R, Brownlee K, Ahern S, Burgel PR, Byrnes C, Colombo C, Corvol H, Cheng S, Daneau G, Elbert A, Faro A, Goss C, Gulmans V, Gutierrez H, de Monestrol I, Jung A, Nährlich L, Kashirskaya N, Marshall B, McKone E, Middleton P, Mondejar-Lopez P, Pastor-Vivero M, Padoan R, Rizvi S, Ruseckaite R, Salvatore M, Stephenson A, da Silva Filho L, Melo J, Zampoli M, Abdrakhmanov O, Harutyunyan S, Carr S. P083 Clinical progression of SARS-CoV-2 infection in people with cystic fibrosis: a global observational study. J Cyst Fibros 2021. [PMCID: PMC8192143 DOI: 10.1016/s1569-1993(21)01110-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
24
|
Kondratyeva E, Efremova A, Melyanovskaya Y, Petrova N, Satsuk N, Bulatenko N, Bukharova T, Zodbinova A, Sherman V, Kashirskaya N, Zinchenko R, Kutsev S, Goldshtein D. Clinical and genetic characterization of patients with cystic fibrosis and functional assessment of the chloride channel with the pathogenic variant c.831G>A (p.Trp277*), described for the first time. Gene 2020; 761:145023. [PMID: 32758581 DOI: 10.1016/j.gene.2020.145023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Revised: 06/07/2020] [Accepted: 07/30/2020] [Indexed: 10/23/2022]
Abstract
The clinical pictures of the disease of two Russian patients with cystic fibrosis with a rare nonsense variant c.831G>A (p.Trp277*) are described. The first case is a patient with the genotype comprising variant c.54-5940_273+10250del21kb (CFTRdele2,3), and the genotype of the second case included variant c.1521_1523delCTT (F508del). Patient 1, whose genotype had two class I genetic variants, revealed severe violations of CFTR synthesis based on the intestinal current measurements (ICM) and results obtained in the intestinal organoids. In both cases of patients with genetic variant c.831G>A, a severe course of cystic fibrosis was observed.
Collapse
Affiliation(s)
- E Kondratyeva
- Research Centre for Medical Genetics, 115522, 1 Moskvorechye St., Moscow, Russia.
| | - A Efremova
- Research Centre for Medical Genetics, 115522, 1 Moskvorechye St., Moscow, Russia
| | - Yu Melyanovskaya
- Research Centre for Medical Genetics, 115522, 1 Moskvorechye St., Moscow, Russia.
| | - N Petrova
- Research Centre for Medical Genetics, 115522, 1 Moskvorechye St., Moscow, Russia
| | - N Satsuk
- Nizhnevartovsk Regional Clinical Children's Hospital, 628609, 30 Severnaya St., Nizhnevartovsk, Russia
| | - N Bulatenko
- Research Centre for Medical Genetics, 115522, 1 Moskvorechye St., Moscow, Russia
| | - T Bukharova
- Research Centre for Medical Genetics, 115522, 1 Moskvorechye St., Moscow, Russia
| | - A Zodbinova
- Research Centre for Medical Genetics, 115522, 1 Moskvorechye St., Moscow, Russia
| | - V Sherman
- Research Centre for Medical Genetics, 115522, 1 Moskvorechye St., Moscow, Russia
| | - N Kashirskaya
- Research Centre for Medical Genetics, 115522, 1 Moskvorechye St., Moscow, Russia
| | - R Zinchenko
- Research Centre for Medical Genetics, 115522, 1 Moskvorechye St., Moscow, Russia
| | - S Kutsev
- Research Centre for Medical Genetics, 115522, 1 Moskvorechye St., Moscow, Russia
| | - D Goldshtein
- Research Centre for Medical Genetics, 115522, 1 Moskvorechye St., Moscow, Russia
| |
Collapse
|
25
|
Barben J, Castellani C, Munck A, Davies JC, de Winter-de Groot KM, Gartner S, Kashirskaya N, Linnane B, Mayell SJ, McColley S, Ooi CY, Proesmans M, Ren CL, Salinas D, Sands D, Sermet-Gaudelus I, Sommerburg O, Southern KW. Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). J Cyst Fibros 2020; 20:810-819. [PMID: 33257262 DOI: 10.1016/j.jcf.2020.11.006] [Citation(s) in RCA: 58] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Revised: 10/30/2020] [Accepted: 11/07/2020] [Indexed: 02/06/2023]
Abstract
Over the past two decades there has been considerable progress with the evaluation and management of infants with an inconclusive diagnosis following Newborn Screening (NBS) for cystic Fibrosis (CF). In addition, we have an increasing amount of evidence on which to base guidance on the management of these infants and, importantly, we have a consistent designation being used across the globe of CRMS/CFSPID. There is still work to be undertaken and research questions to answer, but these infants now receive more consistent and appropriate care pathways than previously. It is clear that the majority of these infants remain healthy, do not convert to a diagnosis of CF in childhood, and advice on management should reflect this. However, it is also clear that some will convert to a CF diagnosis and monitoring of these infants should facilitate their early recognition. Those infants that do not convert to a CF diagnosis have some potential of developing a CFTR-RD later in life. At present, it is not possible to quantify this risk, but families need to be provided with clear information of what to look out for. This paper contains a number of changes from previous guidance in light of developing evidence, but the major change is the recommendation of a detailed assessment of the child with CRMS/CFSPID in the sixth year of age, including respiratory function assessment and imaging. With these data, the CF team can discuss future care arrangements with the family and come to a shared decision on the best way forward, which may include discharge to primary care with appropriate information. Information is key for these families, and we recommend consideration of a further appointment when the individual is a young adult to directly communicate the implications of the CRMS/CFSPID designation.
Collapse
Affiliation(s)
- Jürg Barben
- Paediatric Pulmonology & CF Centre, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland.
| | - Carlo Castellani
- Istituto Giannina Gaslini, IRCCS Istituto Giannina Gaslini, Genova, Italy
| | - Anne Munck
- CF referent physician for the French Society of Newborn Screening, Hopital Necker Enfants-Malades, AP-HP, CF centre, Université Paris Descartes, France
| | - Jane C Davies
- National Heart & Lung Institute, Imperial College London, UK; Royal Brompton and Harefield NHS Foundation Trust, London, UK
| | - Karin M de Winter-de Groot
- Department of Paediatric Pulmonology & Allergology, Wilhelmina Children's Hospital/University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands
| | - Silvia Gartner
- Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Universitari Vall d´Hebron, Barcelona, Spain
| | - Nataliya Kashirskaya
- Laboratory of genetic epidemiology, Research Centre for Medical Genetics, Moscow, Russian Federation
| | - Barry Linnane
- Graduate Entry Medical School and Centre for Interventions in Infection, Inflammation & Immunity (4i), University of Limerick, Limerick, Ireland
| | - Sarah J Mayell
- Regional Paediatric CF Centre, Alder Hey Children's Hospital, Liverpool, UK
| | - Susanna McColley
- Department of Pediatrics, Northwestern University Feinberg School of Medicine, Stanley Manne Children's Research Institute, Ann and Robert H Lurie Children's Hospital of Chicago, USA
| | - Chee Y Ooi
- Discipline of Paediatrics, School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Australia; Department of Gastroenterology and Molecular and Integrative Cystic Fibrosis Research Centre, Sydney Children's Hospital, Randwick, NSW, Australia
| | - Marijke Proesmans
- Division of Woman and Child, Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium
| | - Clement L Ren
- Department of Pediatrics, Indiana University School of Medicine, Division of Pediatric Pulmonology, Allergy and Sleep Medicine, Riley Hospital for Children, Indianapolis, USA
| | - Danieli Salinas
- Department of Pediatric Pulmonology, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, USA
| | - Dorota Sands
- Cystic Fibrosis Department, Institute of Mother and Child, Warsaw, Poland
| | - Isabelle Sermet-Gaudelus
- Institut Necker Enfants Malades/INSERM U1151, Service de Pneumologie et Allergologie Pédiatriques Centre de Référence Maladies Rares, Mucoviscidose et maladies de CFTR, Hôpital Necker Enfants Malades Paris. Université de Paris. ERN Lung, France
| | - Olaf Sommerburg
- Paediatric Pulmonology, Allergology & CF Centre, Department of Paediatrics III, and Translational Lung Research Center, German Lung Research Center, University Hospital Heidelberg, Germany
| | - Kevin W Southern
- Department of Women's and Children's Health, University of Liverpool, UK
| | | |
Collapse
|
26
|
McClenaghan E, Cosgriff R, Brownlee K, Ahern S, Burgel PR, Byrnes CA, Colombo C, Corvol H, Cheng SY, Daneau G, Elbert A, Faro A, Goss CH, Gulmans V, Gutierrez H, de Monestrol I, Jung A, Justus LN, Kashirskaya N, Marshall BC, McKone E, Middleton PG, Mondejar-Lopez P, Pastor-Vivero MD, Padoan R, Rizvi S, Ruseckaite R, Salvatore M, Stephenson AL, Filho LVRDS, Melo J, Zampoli M, Carr SB. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. J Cyst Fibros 2020; 19:868-871. [PMID: 33183965 PMCID: PMC7641525 DOI: 10.1016/j.jcf.2020.10.003] [Citation(s) in RCA: 67] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Revised: 10/21/2020] [Accepted: 10/23/2020] [Indexed: 01/06/2023]
Abstract
With the growing SARS-CoV-2 pandemic, we need to better understand its impact in specific patient groups like those with Cystic Fibrosis (CF). We report on 181 people with CF (32 post-transplant) from 19 countries diagnosed with SARS-CoV-2 prior to 13 June 2020. Infection with SARS-CoV-2 appears to exhibit a similar spectrum of outcomes to that seen in the general population, with 11 people admitted to intensive care (7 post-transplant), and 7 deaths (3 post-transplant). A more severe clinical course may be associated with older age, CF-related diabetes, lower lung function in the year prior to infection, and having received an organ transplant. Whilst outcomes in this large cohort are better than initially feared overall, possibly due to a protective effect of the relatively younger age of the CF population compared to other chronic conditions, SARS-CoV-2 is not a benign disease for all people in this patient group.
Collapse
Affiliation(s)
| | - Rebecca Cosgriff
- Cystic Fibrosis Trust, UK CF Registry, 1 Aldgate, London EC3N 1RE, UK
| | - Keith Brownlee
- Cystic Fibrosis Trust, UK CF Registry, 1 Aldgate, London EC3N 1RE, UK
| | | | - Pierre-Régis Burgel
- Université de Paris, Inserm U1016, Institut Cochin and Cochin Hospital, Assistance Publique Hôpitaux de Paris (APHP), France
| | - Catherine A Byrnes
- Starship Children's Hospital and University of Auckland, Auckland, New Zealand
| | - Carla Colombo
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
| | - Harriet Corvol
- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Assistance Publique Hôpitaux de Paris (APHP), Hôpital Trousseau, Service de Pneumologie Pédiatrique, Paris, France
| | | | | | | | | | | | | | | | | | - Andreas Jung
- University Children's Hospital Zurich, Switzerland
| | | | | | | | | | | | | | | | - Rita Padoan
- Cystic Fibrosis Support Center, Department of Paediatric, University of Brescia, Italy
| | | | | | - Marco Salvatore
- National Center Rare Diseases Undiagnosed Rare Diseases Interdepartmental Unit Istituto Superiore di Sanità, Rome, Italy
| | - Anne L Stephenson
- Cystic Fibrosis Canada, Canada; Toronto Adult Cystic Fibrosis Centre, St. Michael's Hospital, Toronto, Canada
| | | | | | - Marco Zampoli
- University of Cape Town and Red Cross War Memorial Children's Hospital, South Africa
| | | |
Collapse
|
27
|
Amelina E, Krasovskiy S, Kondratieva E, Kashirskaya N, Voronkova A, Starinova M, Seroklinov V, Petrova D, Dauletova J, Sergienko D, Stashkevich T, Ledneva V, Ulyanova L, Ivleva V, Gaimolenko I, Petrova A, Potapova N, Bondarenko T, Shinkareva V, Mambetova A, Maremshanova F, Protasova T, Brisin V, Ljagusha D, Golihina T, Ilenkova N, Chikunov V, Petrov V, Zhekaite E. P039 National Cystic Fibrosis Patients Registry of Russia (RCFPR) from 2011–2018. J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30375-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Kondratyeva E, Melyanovskaya Y, Efremova A, Bulatenko N, Bukharova T, Petrova N, Zodbinova A, Sherman V, Kashirskaya N, Ledneva V, Ulyanova L, Zinchenko R, Goldshtein D, Kutsev S. P009 Clinical and genetic characteristics of cystic fibrosis patients carrying pathogenic variant c.1083G> A (p.Trp361*). J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30346-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Petrova N, Kondratyeva E, Krasovskiy S, Adyan T, Polyakov A, Zodbinova A, Melyanovskaya Y, Kashirskaya N, Amelina E, Starinova M, Voronkova A, Sherman V, Chernyak A, Chepurnaya M, Filimonova T, Smirnova V, Stezhkina E, Vasilieva E, Yakovleva V, Borisov A, Boychenko E, Kozlov A, Odinokova O, Gembitskaya T, Kovalev V, Alimova I, Baykova G, Kozyreva L, Ochirova N, Mankieva L, Lakhova E, Ivakhnenko E, Trishina S, Komlev N, Dyachkova A, Pyaterkina O, Shakirova G, Togochakova O, Yagubyants E, Zinchenko R, Kutsev S. P011 The diversity of large genomic rearrangements of the CFTR gene in Russian patients with cystic fibrosis. J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30348-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
30
|
Chernukha M, Avetisyan L, Shaginyan I, Zhuhovitsky V, Burmistrov E, Medvedeva O, Siyanova E, Polyakov N, Grumov D, Kondratyeva E, Sherman V, Kashirskaya N, Rusakova E, Ginzburg A. P116 Identification difficulties of non-fermenting microorganisms from the respiratory tract of patients with cystic fibrosis. J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30451-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
31
|
Kondratyeva E, Budzinskiy R, Borzova Y, Chernyak A, Voronkova A, Sherman V, Krasovskiy S, Klimko N, Starinova M, Kashirskaya N, Odinaeva N, Kozlova E, Sikora N, Molchanova O, Saczuk N, Revel’-Muroz N, Karimova I, Golubczova O, Pavlov P, Asherova I, Zil’ber I. P110 Characteristics of allergic bronchopulmonary aspergillosis in children of the Russian Federation. J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30445-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
32
|
Colombo C, Alicandro G, Evans H, Oliver M, Ooi C, Alghisi F, Kashirskaya N, Kondratyeva E, Ramm G, de Monestrol I, Padoan R, Asherova I, Lindblad A. WS03.2 A multicentre cohort study on ursodeoxycholic acid and liver disease associated with cystic fibrosis. J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30178-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
33
|
Hatziagorou E, Orenti A, Drevinek P, Kashirskaya N, Mei-Zahav M, De Boeck K, Pfleger A, Sciensano MT, Lammertyn E, Macek M, Olesen HV, Farge A, Naehrlich L, Ujhelyi R, Fletcher G, Padoan R, Timpare Z, Malakauskas K, Fustik S, Gulmans V, Turcu O, Pereira L, Mosescu S, Rodic M, Kayserova H, Krivec U, Vazquez-Cordero C, de Monestrol I, Lindblad A, Jung A, Makukh H, Carr SB, Cosgriff R, Zolin A. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis–data from the European cystic fibrosis society patient registry. J Cyst Fibros 2020; 19:376-383. [DOI: 10.1016/j.jcf.2019.08.006] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 08/02/2019] [Accepted: 08/11/2019] [Indexed: 01/04/2023]
|
34
|
Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel PR, Tullis E, Castaños C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-Hamblett N, Kashirskaya N, Kerem E, Mathew JL, McKone EF, Naehrlich L, Nasr SZ, Oates GR, O'Neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F. The future of cystic fibrosis care: a global perspective. The Lancet Respiratory Medicine 2020; 8:65-124. [DOI: 10.1016/s2213-2600(19)30337-6] [Citation(s) in RCA: 351] [Impact Index Per Article: 87.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Revised: 07/19/2019] [Accepted: 08/14/2019] [Indexed: 02/06/2023]
|
35
|
Petrova N, Kondratyeva E, Krasovskiy S, Polyakov A, Adyan T, Ivaschenko T, Pavlov A, Zinchenko R, Ginter E, Odinokova O, Nazarenko L, Kapranov N, Sherman V, Amelina E, Kashirskaya N, Voronkova A, Zodbinova A, Chernyak A, Kutsev S, Novikova O, Alimova I, Vodovozova E, Ledeneva L, Enina E, Ponomareva T, Oganesyan I, Kanukova N, Aleksanyan M, Zakurnaeva E, Filimonova M, Smirnova I, Mukhacheva V, Kalinina Y, Bulatova I, Tryastsyna N. P016 Novel CFTR genetic variants in cystic fibrosis patients from the Russian Federation (according to the Cystic Fibrosis Patients Register of the Russian Federation in 2017). J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30311-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Kondratyeva E, Petrova N, Krasovskiy S, Polyakov A, Sherman V, Amelina E, Kashirskaya N, Voronkova A, Starinova M, Pavlov A, Golubtsova O, Ivachnenko E, Trishina S, Komlev N, Dyachkova A, Pyaterkina O, Kadyrova D, Togochakova O, Yagubyants E, Chepurnaya M, Filimonova T, Smirnova V, Stezhkina E, Vasil'yeva E, Yakovleva V, Borisov A, Kondratenko O, Boychenko E, Kozlov A, Krasko O. P008 Characteristics of patients, carriers of genetic variant E92K. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30303-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
37
|
Zinchenko R, Petrova N, Vasilyeva T, Kashirskaya N, Kondratyeva E, Voronkova A, Sherman V, Marakhonov A, Galkina V, Ginter E. P011 Comprehensive analysis of CFTR mutation spectrum in Russians. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30306-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Kondratyeva E, Krasovskiy S, Petrova N, Polyakov A, Stepanova A, Amelina E, Adyan T, Chernyak A, Voronkova A, Starinova M, Sherman V, Zhekaite E, Kashirskaya N, Kutsev S, Zodbinova A, Boitsova E, Gembitskaya T, Moskvina D, Stepanenko T, Filippova T, Konovalova L, Makhmutova V, Orlov A, Pashkevich A, Nikitina M, Kovalev V, Ignatieva M, Ushatskaya O, Borisenko T, Antipova L, Ponomareva N, Shulyak I. P009 Characteristics of genetic variant 3272-16T > A according to the register of patients with cystic fibrosis in 2017. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30304-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
39
|
Kashirskaya N, Krasovskiy S, Kondratyeva E, Amelina E, Voronkova A, Chernyak A, Kapranov N, Starinova M, Sherman V, Simanova T, Osipova E, Starodubtseva O, Muraleva N, Kochergina T, Gogoleva E, Gubareva T, Kozlova E, Sikora N, Molchanova O, Satsuk N, Revel-Muroz N, Karimova I, Golubtsova O, Pavlov P, Asherova I, Zilber I, Gembitskaya T, Petrova N, Ginter E, Kutsev S, Zinchenko R. P061 The significance of the National Cystic Fibrosis Patient Registry for the optimisation of care for patients with cystic fibrosis in the Russian Federation. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30355-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Kondratyeva E, Krasovskiy S, Petrova N, Kashirskaya N, Amelina E, Polyakov A, Ivaschenko T, Pavlov A, Zinchenko R, Ginter E, Odinokova O, Nazarenko L, Kapranov N, Sherman V, Chernyak A, Voronkova A, Starinova M, Izhevskaya V, Zodbinova A, Melyanovskaya Y, Kutsev S, Romanenko N, Pinegina Y, Korneeva T, Safonova T, Shevlyakova A, Pavlinova E, Rybalkina M, Skachkova M, Furman E, Shadrina V, Vasil'yeva T, Voronin S, Baykova G, Kozyreva L, Ochirova N, Mankieva L, Lachova E, Tutueva L. P006 Characteristic of genetic variants of patients with cystic fibrosis of the Russian Federation according to the 2017 register and the possibility of targeted therapy. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30301-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
41
|
Semykin S, Goryainova A, Kashirskaya N. P003 New mutations in the CFTR gene. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30298-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
42
|
Krasovskiy S, Cherniak A, Kashirskaya N, Kondratyeva E, Amelina E, Voronkova A, Starinova M, Brisin V, Lyagusha D, Golihina T, Ilyenkova N, Chikunov V, Vasilyuk N, Svetlichnaya I, Zhekayte E, Sherman V, Gorinova Y, Simonova O, Zonenko O, Semykin S, Mukhina M, Lavrova A, Erzutova M, Kondakova Y, Kutsev S, Petrova N, Zinchenko R, Polyakov A, Adyan T. P007 Features of the clinical course of cystic fibrosis due to the severity of the genotype (according to the Cystic Fibrosis Patient Registry of the Russian Federation (2017)). J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30302-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
43
|
Layer P, Kashirskaya N, Gubergrits N. Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency. World J Gastroenterol 2019; 25:2430-2441. [PMID: 31171887 PMCID: PMC6543241 DOI: 10.3748/wjg.v25.i20.2430] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 04/02/2019] [Accepted: 04/20/2019] [Indexed: 02/06/2023] Open
Abstract
The objective of this study was to analyze the current evidence for the use of pancreatic enzyme replacement therapy (PERT) in affecting survival and quality of life in patients with pancreatic exocrine insufficiency (PEI). Systematic searches of the literature were performed using the PubMed database. Articles were selected for inclusion if they reported findings from trials assessing the effects of PERT on quality of life, survival, malabsorption, growth parameters (such as height, body weight and body mass index), or gastrointestinal symptoms (such as abdominal pain, stool consistency and flatulence). PERT improved PEI-related malabsorption and weight maintenance in patients with cystic fibrosis, chronic pancreatitis, pancreatic cancer, and post-surgical states. In patients with chronic pancreatitis, PERT improved PEI-related symptoms and quality of life measures. Several small retrospective studies have also suggested that PERT may have a positive impact on survival, but long-term studies assessing this effect were not identified. PERT is effective for treating malnutrition and supporting weight maintenance, and it is associated with improved quality of life and possibly with enhanced survival in patients with PEI. However, there is evidence that not all patients with PEI receive adequate PERT. Future work should aim to assess the long-term effects of PERT on the survival of patients with PEI.
Collapse
Affiliation(s)
- Peter Layer
- Department of Internal Medicine, Israelitic Hospital, Hamburg 22297, Germany
| | - Nataliya Kashirskaya
- Department of Genetic Epidemiology (Cystic Fibrosis group), Federal State Budgetary Institution “Research Centre for Medical Genetics”, Moscow 115522, Russia
| | - Natalya Gubergrits
- Department of Internal Medicine, Donetsk National Medical University, Lyman 83001, Ukraine
| |
Collapse
|
44
|
Zolin A, Bossi A, Cirilli N, Kashirskaya N, Padoan R. Cystic Fibrosis Mortality in Childhood. Data from European Cystic Fibrosis Society Patient Registry. Int J Environ Res Public Health 2018; 15:ijerph15092020. [PMID: 30223583 PMCID: PMC6163251 DOI: 10.3390/ijerph15092020] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Revised: 08/29/2018] [Accepted: 09/07/2018] [Indexed: 12/03/2022]
Abstract
Data collected in the European Cystic Fibrosis Society Patient Registry (ECFSPR) database were used to investigate whether risk factors for death in childhood and adolescents CF patients have different impact in countries of different income. In this way, it is possible to recognize where interventions could improve the quality of care and survival in these patients. We matched deceased and alive patients by age, country, year of follow-up. Multivariable logistic models were developed. In the years of this study, the ECFSPR collected information on 24,416 patients younger than 18 years: 7830 patients were from countries with low/middle income and 16,586 from countries with high income; among these the dead are 102 and 107 (p < 0.001), respectively. The use of oxygen, forced expiratory volume in one second (FEV1) below 40% and BMI standard deviation score (SDS) below −2 represent risk factors for death. However, some patients from countries with high income remain alive even if their values of FEV1% and BMI-SDS were low, and some deceased patients from countries with high income had high values of FEV1% (>60%). Evaluation of mortality in pediatric age may reflect the availability of resources for CF diagnosis and treatment in some countries.
Collapse
Affiliation(s)
- Anna Zolin
- Department of Clinical Sciences and Community Health, University of Milan, Milano 20133, Italy.
| | - Anna Bossi
- Department of Clinical Sciences and Community Health, University of Milan, Milano 20133, Italy.
| | - Natalia Cirilli
- Cystic Fibrosis Centre, Mother-Child Department, United Hospitals, Via Conca, 71, Torrette di Ancona I-60126, Italy.
| | - Nataliya Kashirskaya
- Laboratory of Genetic Epidemiology, Federal State Scientific Budgetary Institution «Research Centre for Medical Genetics», Moscow 115522, Russia.
| | - Rita Padoan
- Cystic Fibrosis Unit, Pediatric Department, ASST Spedali Civili Brescia, piazzale Spedali Civili, Brescia 25123, Italy.
| |
Collapse
|
45
|
Goryainova A, Kashirskaya N, Belmer S, Semykin S. EPS2.03 The influence of polymorphism of metalloproteinase genes on the formation of CF-liver cirrhosis and CF pneumofibrosis. J Cyst Fibros 2018. [DOI: 10.1016/s1569-1993(18)30240-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
46
|
Kutsev S, Kondratyeva E, Petrova N, Zinchenko R, Kashirskaya N, Gembitskaya T, Voronkova A, Sherman V, Chernyak A, Krasovsky S, Amelina E, Budzynskiy R, Golubtsova O, Pavlov P, Korneyeva T, Safonova T, Shevlyakova A, Pavlinova E, Protasova T, Vasilyeva T, Voronin S, Sergienko D, Ilyenkova N, Chikunov V, Rybalkina M, Skachkova M, Brisin V, Lyagusha D, Kondakova J, Romanenko N, Pinegina Y, Merzlova N, Shadrina V, Asherova I, Zilber I, Melyanovskaya Y. P259 Characteristics of the frequency of homozygotes F508del according to the register of patients with cystic fibrosis of the Russian Federation in 2016. J Cyst Fibros 2018. [DOI: 10.1016/s1569-1993(18)30554-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
47
|
Kondratyeva E, Chernyak A, Krasovskiy S, Gembitskaya T, Voronkova A, Sherman V, Amelina E, Budzynskiy R, Zhekayte E, Kashirskaya N, Osipova E, Starodubtseva O, Simanova T, Kutyavina S, Kochergina T, Revel-Muroz N, Karimova I, Kalinina J, Basilaya A, Dyachkova A, Satsuk N, Neretina A, Ledneva V, Ivleva V, Borisenko T, Ignatieva M, Ushatskaya O, Kovalev V, Nikitina M, Pashkevich A, Orlov A, Zinchenko J, Konovalova L, Filippova T. P262 The characteristics of chronic respiratory infection by Pseudomonas aeruginosa in the Register of the Patients with CF in the Russian Federation in 2016. J Cyst Fibros 2018. [DOI: 10.1016/s1569-1993(18)30557-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
48
|
Repina S, Krasovsky S, Rozhivanov R, Bogoliubov S, Sorokina T, Andreeva M, Shtaut M, Kurilo L, Shmarina G, Adyan T, Stepanova A, Polyakov A, Amelina E, Kapranov N, Kondrateva E, Kashirskaya N, Chernykh V. WS17.6 Characteristics of the reproductive system in adult male patients with cystic fibrosis. J Cyst Fibros 2018. [DOI: 10.1016/s1569-1993(18)30219-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Maksimysheva T, Kondratyeva E, Voronkova A, Melyanovskaya Y, Sherman V, Zhekayte E, Chernyak A, Nazarenko L, Odinokova O, Smirnova I, Mukhacheva V, Nikonova V, Shabalova L, Gorinova Y, Simonova O, Usacheva M, Zonenko O, Semykin S, Mukhina M, Lavrova A, Erzutova M, Baykova G, Kozyreva L, Boytsova E, Moskvina D, Stepanenko T, Gembitskaya T, Amelina E, Kashirskaya N, Krasovsky S. P201 Features of somatic growth of children with CF in different age periods in the Russian Federation. J Cyst Fibros 2018. [DOI: 10.1016/s1569-1993(18)30496-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
50
|
Avetisyan L, Chernukha M, Siyanova E, Shaginyan I, Prilipov A, Kondratyeva E, Kashirskaya N, Zhekayte E, Krasovsky S, Usacheva M. P039 Monitoring of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients. J Cyst Fibros 2018. [DOI: 10.1016/s1569-1993(18)30336-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|